7747.T

The company maintains a strong liquidity position, with a current ratio of 3.71, indicating a robust ability to meet short-term obligations. Its cash and equivalents amount to 54.2 billion JPY, which is a significant portion of its total assets, further supporting its liquidity. The debt-to-equity ratio is 0.08, suggesting a conservative capital structure with minimal reliance on debt financing.

In terms of profitability, the company's return on equity (ROE) is 8.46%, and its return on assets (ROA) is 6.59%, both of which are indicators of efficient use of equity and assets to generate profit. The operating income of 19.15 billion JPY and net income of 12.74 billion JPY reflect a healthy margin, with the gross profit margin at 67.7%. These figures are in line with the industry's preferred metrics, indicating that the company is performing well relative to its peers.

The company's revenue is concentrated in the healthcare services and equipment industry, with no significant diversification into other sectors. This concentration may expose the company to industry-specific risks, but it also allows for focused expertise and market penetration. The geographic exposure is not specified, but the company's operations are primarily within Japan, given the JPY financials.

The company's growth trajectory is positive, with a revenue of 120.03 billion JPY. While specific growth rates are not provided, the operating cash flow of 40.54 billion JPY and free cash flow of 8.83 billion JPY suggest a strong cash-generating capability. The capital expenditure of -8.58 billion JPY indicates that the company is investing in its operations, which could support future growth.

The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's conservative capital structure and strong cash reserves mitigate the risk of liquidity issues. The dilution potential is also low, as the number of shares outstanding has not changed between basic and diluted shares. This suggests that the company is not likely to issue additional shares in the near term, preserving shareholder value.

Recent events, such as analyst estimates, show a positive outlook with a mean price target of 3,803.57 JPY and a median price target of 4,000.00 JPY. The mean recommendation of 2.06, with 12 buy ratings and 3 hold ratings, indicates that analysts are generally optimistic about the company's future performance. These estimates suggest that the market expects the company to continue its strong performance and potentially increase in value.